» Articles » PMID: 30211029

Unique Interstitial MiRNA Signature Drives Fibrosis in a Murine Model of Autosomal Dominant Polycystic Kidney Disease

Overview
Journal World J Nephrol
Specialty Nephrology
Date 2018 Sep 14
PMID 30211029
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To delineate changes in miRNA expression localized to the peri-cystic local microenvironment (PLM) in an orthologous mouse model of autosomal dominant polycystic kidney disease (ADPKD) ( ).

Methods: We profiled miRNA expression in the whole kidney and laser captured microdissection (LCM) samples from PLM in kidneys with Qiagen miScript 384 HC miRNA PCR arrays. The three times points used are: (1) post-natal (PN) day 21, before the development of trichrome-positive areas; (2) PN28, the earliest sign of trichrome staining; and (3) PN42 following the development of progressive fibrosis. PN21 served as appropriate controls and as the reference time point for comparison of miRNA expression profiles.

Results: LCM samples revealed three temporally upregulated miRNAs [2 to 2.75-fold at PN28 and 2.5 to 4-fold ( ≤ 0.05) at PN42] and four temporally downregulated miRNAs [2 to 2.75 fold at PN28 and 2.75 to 5-fold ( ≤ 0.05) at PN42]. Expression of twenty-six miRNAs showed no change until PN42 [six decreased (2.25 to 3.5-fold) ( ≤ 0.05) and 20 increased (2 to 4-fold) ( ≤ 0.05)]. Many critical miRNA changes seen in the LCM samples from PLM were not seen in the contralateral whole kidney.

Conclusion: Precise sampling with LCM identifies miRNA changes that occur with the initiation and progression of renal interstitial fibrosis (RIF). Identification of the target proteins regulated by these miRNAs will provide new insight into the process of fibrosis and identify unique therapeutic targets to prevent or slow the development and progression of RIF in ADPKD.

Citing Articles

Non-coding RNAs as potential biomarkers and therapeutic targets in polycystic kidney disease.

Zheng Q, Reid G, Eccles M, Stayner C Front Physiol. 2022; 13:1006427.

PMID: 36203940 PMC: 9531119. DOI: 10.3389/fphys.2022.1006427.


A Brief Review on the Regulatory Roles of MicroRNAs in Cystic Diseases and Their Use as Potential Biomarkers.

Ruiz-Manriquez L, Ledesma Pacheco S, Medina-Gomez D, Uriostegui-Pena A, Estrada-Meza C, Bandyopadhyay A Genes (Basel). 2022; 13(2).

PMID: 35205236 PMC: 8872411. DOI: 10.3390/genes13020191.


miR‑212 promotes renal interstitial fibrosis by inhibiting hypoxia‑inducible factor 1‑α inhibitor.

Zhang Y, Zhang G, Che L, Shi S, Li Y Mol Med Rep. 2021; 23(3).

PMID: 33495813 PMC: 7809912. DOI: 10.3892/mmr.2021.11828.

References
1.
Liu Y . Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006; 69(2):213-7. DOI: 10.1038/sj.ki.5000054. View

2.
Tan Y, Blumenfeld J, Rennert H . Autosomal dominant polycystic kidney disease: genetics, mutations and microRNAs. Biochim Biophys Acta. 2011; 1812(10):1202-12. DOI: 10.1016/j.bbadis.2011.03.002. View

3.
Harskamp L, Gansevoort R, Boertien W, van Oeveren W, Engels G, Goor H . Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. Clin J Am Soc Nephrol. 2015; 10(10):1749-56. PMC: 4594078. DOI: 10.2215/CJN.09941014. View

4.
Bae K, Park B, Sun H, Wang J, Tao C, Chapman A . Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2013; 8(7):1089-97. PMC: 3700699. DOI: 10.2215/CJN.10561012. View

5.
Patel V, Williams D, Hajarnis S, Hunter R, Pontoglio M, Somlo S . miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A. 2013; 110(26):10765-70. PMC: 3696812. DOI: 10.1073/pnas.1301693110. View